| Financial Information Relating to Reportable Segments |
Following is financial information relating to the Company’s
reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Quarter
Ended |
|
|
Nine Months
Ended |
|
| |
|
March 31, |
|
|
March 31, |
|
| |
|
2014 |
|
|
2013 |
|
|
2014 |
|
|
2013 |
|
|
External sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
80,134 |
|
|
$ |
75,285 |
|
|
$ |
223,881 |
|
|
$ |
214,416 |
|
|
Clinical Controls
|
|
|
15,421 |
|
|
|
5,707 |
|
|
|
41,359 |
|
|
|
16,684 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net sales
|
|
$ |
95,555 |
|
|
$ |
80,992 |
|
|
$ |
265,240 |
|
|
$ |
231,100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
44,593 |
|
|
$ |
43,246 |
|
|
$ |
120,589 |
|
|
$ |
117,123 |
|
|
Clinical Controls
|
|
|
3,157 |
|
|
|
2,247 |
|
|
|
7,225 |
|
|
|
6,498 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment earnings before income taxes
|
|
|
47,750 |
|
|
|
45,493 |
|
|
|
127,814 |
|
|
|
123,621 |
|
|
Unallocated corporate expenses and equity method investee
losses
|
|
|
(1,681 |
) |
|
|
(1,027 |
) |
|
|
(5,873 |
) |
|
|
(3,723 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated earnings before income taxes
|
|
$ |
46,069 |
|
|
$ |
44,466 |
|
|
$ |
121,941 |
|
|
$ |
119,898 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|